Y Intercept Hong Kong Ltd Sells 3,854 Shares of Natera, Inc. $NTRA

Y Intercept Hong Kong Ltd cut its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 38.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,156 shares of the medical research company’s stock after selling 3,854 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Natera were worth $991,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Hilltop National Bank purchased a new stake in Natera during the 2nd quarter worth approximately $33,000. Sound Income Strategies LLC lifted its stake in shares of Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after buying an additional 110 shares during the period. Quent Capital LLC acquired a new stake in shares of Natera during the third quarter worth $46,000. N.E.W. Advisory Services LLC grew its holdings in shares of Natera by 256.8% during the second quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after buying an additional 226 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of Natera by 23.1% in the 3rd quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 81 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, insider Solomon Moshkevich sold 23,205 shares of the business’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,447,141.70. Following the completion of the sale, the insider owned 144,992 shares of the company’s stock, valued at approximately $34,035,422.08. The trade was a 13.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Roelof Botha sold 75,000 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $236.12, for a total transaction of $17,709,000.00. Following the transaction, the director owned 1,154,198 shares of the company’s stock, valued at $272,529,231.76. This represents a 6.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 350,703 shares of company stock worth $82,221,116. Insiders own 5.63% of the company’s stock.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES?EMB heart?transplant trial — a clinical milestone for the transplant franchise (Prospera) that de?risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short?term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Natera Stock Performance

Shares of Natera stock opened at $231.14 on Monday. The firm has a 50-day simple moving average of $235.91 and a two-hundred day simple moving average of $194.43. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The company has a market cap of $31.97 billion, a P/E ratio of -100.93 and a beta of 1.64.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.25). The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.26) EPS. Equities research analysts forecast that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Ratings Changes

Several analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price target on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Canaccord Genuity Group reiterated a “buy” rating on shares of Natera in a report on Monday, January 12th. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Piper Sandler upped their price objective on shares of Natera from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, BTIG Research increased their price objective on shares of Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday, December 5th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $249.20.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.